These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3331376)

  • 1. Design of antiandrogens and their mechanisms of action: a case study (anandron).
    Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
    Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
    Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F
    Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
    Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
    Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and clinical studies with RU 23908 (Anandron).
    Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
    Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
    Huot RI; Shain SA
    Cancer Res; 1986 Aug; 46(8):3775-81. PubMed ID: 2942235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
    Steinsapir J; Mora G; Muldoon TG
    Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
    Moguilewsky M; Tournemine C
    Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
    Ayub M; Levell MJ
    J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
    Bentel JM; Birrell SN; Pickering MA; Holds DJ; Horsfall DJ; Tilley WD
    Mol Cell Endocrinol; 1999 Aug; 154(1-2):11-20. PubMed ID: 10509795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens, antiandrogens and androgen receptor abnormalities.
    Kuil CW; Brinkmann AO
    Eur Urol; 1996; 29 Suppl 2():78-82. PubMed ID: 8717468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens.
    Brown TR; Rothwell SW; Sultan C; Migeon CJ
    Steroids; 1981 Jun; 37(6):635-48. PubMed ID: 6457421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.